Coronavirus

Relaxing patent rights in a pandemic is a win for innovators and the public

The long read: Womble Bond Dickinson’s Ben Bourke takes a deep dive into how life science companies have handled their IP portfolios over the covid-19 pandemic – in particular Moderna Therapeutics’ pledge not to enforce patents relating to its vaccine – and examines how such adjustments can prepare the ground for future inventions

Relaxing patent rights in a pandemic is a win for innovators and the public
Europe is seeing a boom in pharma and biotech patenting
25 Mar 2021

Europe is seeing a boom in pharma and biotech patenting

A surge in life sciences applications offset a disappointing performance in other areas, the latest EPO statistics suggest

We worked at triple speed on vaccine patent strategy to help the world, says BioNTech IP chief
16 Mar 2021

We worked at triple speed on vaccine patent strategy to help the world, says BioNTech IP chief

“You could go through a practice of 30 years, never experiencing what we have just been through in a year,” says Julie Anne Gillespie in exclusive interview alongside colleague James Ryan

Latest

View all
9 Mar 2021

Covid-19 patent landscape confusion is a big concern for life sciences organisations

Providing new insights into recent filings, but patent landscape uncertainties may pose dangers in the wake of the pandemic Read more

3 Mar 2021

UK court clarifies when patents can be used without owner authorisation for “the service of the crown”

Concerns that rarely deployed Crown Use might become more commonplace have been significantly alleviated after appeals judges deliver ruling in IPCom v Vodafone Read more

2 Mar 2021

Negotiating patent licensing agreements during a pandemic

Co-published - Although some major deals in the semiconductor space have been concluded over the last year, respondents to a survey on virtual negotiations see major difficulties in online discussions Read more

1 Mar 2021

Japan records 6% decline in patent filings for 2020

Preliminary figures also show a drop in PCT filings naming JPO as the receiving office Read more

News

View all
19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

16 Nov 2020

Moderna's covid vaccine is promising news, but IP issues may mean the financial windfall it enjoys are limited

A major PTAB defeat and uncertainties around US government funding cast a royalties shadow over the company's ability to monetise the breakthrough Read more

9 Nov 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome Read more

6 Nov 2020

Budget pressures accelerate Japan Inc’s IP strategy re-think

Leading lights from Canon, Hitachi and NTT among those who will discuss the way forward at virtual IPBC Japan conference Read more

Analysis

View all
6 Feb 2021

No, IP rights are not the barrier to covid-19 vaccine supplies

Continued criticism of biopharma patent owners fails to acknowledge that manufacturing and supply complexities are the real obstacles to mass inoculation around the world Read more

30 Dec 2020

The biggest life sciences IP stories of 2020

Although the year was dominated by the response to covid-19, there were other major developments as well Read more

22 Dec 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies. Read more

12 Nov 2020

How Lenovo is deploying patent data to support its diversity and inclusion efforts

IP team led by John Mulgrew is taking a hard look at inventorship within the company as part of an effort to attract and retain a diverse R&D talent pool Read more

Insights

View all
8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more